TFPI-2 Downregulates Multidrug Resistance Protein in 5-FU-Resistant Human Hepatocellular Carcinoma BEL-7402/5-FU Cells

Anatomical Record

Volumn 296, Issue 1, 2013, Pages 56-63

  Lu, Fei ^a   Hou, Yong Qiang ^a   Song, Ying ^a   Yuan, Zheng Jiang ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

BEL 7402 5 FU cell; Human hepatocellular carcinoma; Multidrug resistance; TFPI 2

Indexed keywords

BETA ACTIN; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUTATHIONE TRANSFERASE; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PLACENTA PROTEIN 5; RHODAMINE 123;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; SERINE PROTEINASE INHIBITORS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 84871667028     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22611     Document Type: Article

References (24)

1. Achari C, Reddy GV, Reddy TC, Reddanna P. 2011. Chebulagic acid synergizes the cytotoxicity of doxorubicin in human hepatocellular carcinoma through COX-2 dependant modulation of MDR-1. Med Chem 5: 432-442.
2. Bulavin DV, Fornace AJ, Jr. 2004. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92: 95-118.
3. Carew MW, Naranmandura H, Shukalek CB, Le XC, Leslie EM. 2011. Monomethylarsenic diglutathione transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Drug Metab Dispos 12: 2298-2304.
4. Chai H, Pan J, Zhang X, Zhang X, Shen X, Li H, Zhang K, Yang C, Sheng H, Gao H. 2012. ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. Int J Clin Exp Med 2: 186-194.
5. Clark FS, Parkinson T, Hitchcock CA, Gow NA. 1996. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother 40: 419-425.
6. Dussault AA, Pouliot M. 2006. Rapid and simple comparison of messenger RNA levels using real-time PCR. Biol Proced Online 8: 1-10.
7. Filomeni G, Turella P, Dupuis ML, Forini O, Ciriolo MR, Cianfriglia M, Pezzola S, Federici G, Caccuri AM. 2008. 6-(7-Nitro-2, 1, 3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Mol Cancer Ther 2: 371-379.
8. Hong L, Piao Y, Han Y, Wang J, Zhang X, Du Y, Cao S, Qiao T, Chen Z, Fan D. 2005. Zinc ribbon domain containing 1 (ZNRD1) mediates multi-drug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther 4: 1936-1942.
9. Jiao JW, Wen F. 2011. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncol Rep 3: 781-788.
10. Krawczyk P, Wojas-Krawczyk K, Mlak R, Kucharczyk T, Biernacka B, Milanowski J. 2012. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer-a pilot study. Folia Histochem Cytobiol 1: 80-86.
11. Laborde E. 2010. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ 17: 13173-13180.
12. Li H, Hui L, Xu W, Shen H, Chen Q, Long L, Zhu X. 2012. Modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells. Oncol Lett 2: 485-489.
13. Li M, Li X, Li JC. 2010. Possible mechanisms of trichosanthin-induced apoptosis of tumor cells. Anat Rec (Hoboken) 6: 986-992.
14. Losert A, Lötsch D, Lackner A, Koppensteiner H, Peter-Vörösmarty B, Steiner E, Holzmann K, Grunt T, Schmid K, Marian B, Grasl-Kraupp B, Schulte-Hermann R, Krupitza G, Berger W, Grusch M. 2012. The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Lett 2: 164-172.
15. Oga EF, Sekine S, Shitara Y, Horie T. 2012. Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells. Am J Trop Med Hyg 1: 64-69.
16. Ozkan C, Gumuskaya B, Yaman S, Aksoy S, Guler G, Altundag K. 2012. ERCC1 expression in triple negative breast cancer. J BUON 2: 271-276.
17. Rabik CA, Dolan ME. 2007. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23.
18. Ran Y, Pan J, Hu H, Zhou Z, Sun L, Peng L, Yu L, Sun L, Liu J, Yang Z. 2009. A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma. Hum Gene Ther 20: 41-49.
19. Turner JG, Dawson J, Sullivan DM. 2012. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 8: 1021-1032.
20. Wang S, Xiao X, Zhou X, Huang T, Du C, Yu N, Mo Y, Lin L, Zhang J, Ma N, Murata M, Huang G, Zhang Z. 2010. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 10: 617.
21. Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, Tung EK, Ching YP, Ng IO. 2007. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45: 1129-1138.
22. Wu N, Gu C, Gu H, Hu H, Han Y, Li Q. 2011. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 6: 482-490.
23. Xu D, Lu Q, Hu X. 2006. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett 243: 274-280.
24. Zhu WY, Hunag YY, Liu XG, He JY, Chen DD, Zeng F, Zhou JH, Zhang YK. 2012. Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer. Anat Rec (Hoboken) 2: 208-214.